UY39863A - Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus - Google Patents

Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus

Info

Publication number
UY39863A
UY39863A UY0001039863A UY39863A UY39863A UY 39863 A UY39863 A UY 39863A UY 0001039863 A UY0001039863 A UY 0001039863A UY 39863 A UY39863 A UY 39863A UY 39863 A UY39863 A UY 39863A
Authority
UY
Uruguay
Prior art keywords
compounds
compositions
treatment
coronavirus
related diseases
Prior art date
Application number
UY0001039863A
Other languages
English (en)
Spanish (es)
Inventor
Lei Shi
Bo Liu
Matthew James Hesse
Denghui Bao
Fengfeng Guo
Viktor Hornak
Sajan Joseph
Jr Thomas Martin Kirrane
Haiyao Lin
yanan Miao
Heinz Ernst Moser
Julien Papillon
Yang Qu
Jun Yuan
Teng Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY39863A publication Critical patent/UY39863A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001039863A 2021-07-22 2022-07-19 Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus UY39863A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163224793P 2021-07-22 2021-07-22
US202163289009P 2021-12-13 2021-12-13

Publications (1)

Publication Number Publication Date
UY39863A true UY39863A (es) 2023-02-28

Family

ID=82742919

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039863A UY39863A (es) 2021-07-22 2022-07-19 Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus

Country Status (11)

Country Link
US (1) US20250092016A1 (enExample)
EP (1) EP4373814A1 (enExample)
JP (1) JP2024527424A (enExample)
KR (1) KR20240038996A (enExample)
AU (1) AU2022315058A1 (enExample)
CA (1) CA3226758A1 (enExample)
MX (1) MX2024000986A (enExample)
PY (1) PY2261702A (enExample)
TW (1) TW202321210A (enExample)
UY (1) UY39863A (enExample)
WO (1) WO2023002409A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7559223B2 (ja) 2020-08-24 2024-10-01 ギリアード サイエンシーズ, インコーポレイテッド リン脂質化合物及びその使用
TWI925033B (zh) 2020-10-16 2026-05-11 美商基利科學股份有限公司 磷脂化合物及其用途
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
AU2023249953A1 (en) 2022-04-08 2024-10-24 Shionogi & Co., Ltd. Uracil derivative having viral growth inhibitory activity and pharmaceutical composition containing same
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds
CR20250040A (es) 2022-08-05 2025-03-18 Gilead Sciences Inc Inhibidores de la proteasa principal de sars-cov2
WO2025125695A2 (en) * 2024-12-17 2025-06-19 Medchemica Consultancy Ltd Chemical compoundsid50000167790940 p. doc 2025-05-07 filing no.:19

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1200825B (de) * 1962-01-13 1965-09-16 Hoechst Ag Verfahren zur Herstellung von 3, 5-Dioxo-triazolidinen
PE20121048A1 (es) * 2009-06-26 2012-08-25 Novartis Ag Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17

Also Published As

Publication number Publication date
AU2022315058A1 (en) 2024-02-08
MX2024000986A (es) 2024-02-12
WO2023002409A1 (en) 2023-01-26
CA3226758A1 (en) 2023-01-26
US20250092016A1 (en) 2025-03-20
EP4373814A1 (en) 2024-05-29
PY2261702A (es) 2023-06-14
KR20240038996A (ko) 2024-03-26
TW202321210A (zh) 2023-06-01
JP2024527424A (ja) 2024-07-24

Similar Documents

Publication Publication Date Title
PY2261702A (es) Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus
CO2026004964A2 (es) Moduladores de kras
BR112022012106A2 (pt) Inibidores de sos1
MX2024008551A (es) Terapias de combinacion.
MX2021002804A (es) Terapias de combinacion.
MX2023001689A (es) Inhibidores de bcl-2.
CL2020001349A1 (es) Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574)
MX2024012801A (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
UY38403A (es) Moduladores de la alfa-1 antitripsina
CL2022002695A1 (es) Inhibidores de rip1k
MX2020011868A (es) Inhibidores de los receptores erbb.
MX2020007947A (es) Inhibidores de erbb/btk.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
DOP2002000525A (es) Inhibidores del factor xa y de otras proteasas de serina implicadas en la cascada de la coagulacion.
MX2022013081A (es) Compuestos para el tratamiento de sars.
CO2020015377A2 (es) Moduladores de la expresión de apol1
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
UY27800A1 (es) Utilizacion de inhibidores de la transduccion de senales inducida por egfr para el tratamiento de la hiperplasia de la prostata benigna (hps) /hipertrofia de la prostata.
CL2022000214A1 (es) Inhibidores de enzimas
CO2022000270A2 (es) Inhibidores de enzimas
CO2022000266A2 (es) Inhibidores de enzimas
PA8555501A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
CO2023012342A2 (es) Inhibidores de enzimas